Dose de-escalation improved patient-reported outcomes in early p16-positive oropharyngeal cancer
Reducing radiotherapy from 70 Gy to 60 Gy was associated with better one-year swallowing outcomes and lower acute toxicity in selected patients.
Reducing radiotherapy from 70 Gy to 60 Gy was associated with better one-year swallowing outcomes and lower acute toxicity in selected patients.
Longer pembrolizumab exposure after chemoradiation was associated with lower mortality, but immortal time bias prevents causal interpretation.
Anatomy- and dose-based machine learning predicted gamma passing rates accurately for organs at risk, but less reliably for target volumes.
Single-fraction proton treatment produced pain responses without grade 2 or higher related toxicity in 10 patients with thoracic bone metastases.
In mice, ultrahigh dose-rate X-rays caused less early testicular damage than conventional irradiation, with protection linked to ferroptosis suppression.
Normal-tissue sparing with ultrahigh dose-rate radiotherapy remains conditional and cannot replace conformal dosimetry, organ-at-risk constraints, or rigorous quality assurance.
Dynamic collimation improved target-region contrast and signal-to-noise ratio while preserving full-field information without increasing the total photon budget.
Adding vaginal cuff brachytherapy to whole pelvis radiation therapy was associated with improved overall survival in stage II endometrioid endometrial cancer.
Semi-automated trajectory planning reduced workflow time and needle use while maintaining clinically acceptable target coverage and organ-at-risk doses.
Risk-adapted esophagus-sparing radiotherapy maintained target coverage, with grade 3 esophagitis in only 1.25% of high-risk patients.
Bone marrow-sparing planning reduced pelvic marrow dose, but heterogeneous evidence did not confirm a consistent reduction in hematologic toxicity.
A reusable positioning pouch displaced the genitalia from the treatment field while receiving high satisfaction ratings from patients and radiation therapists.
Four-dimensional prompt-gamma imaging detected clinically relevant proton range shifts associated with anatomical change during pancreatic proton therapy.
A single 19-Gy fraction achieved 92.9% three-year biochemical relapse-free survival with limited grade 2 gastrointestinal and genitourinary toxicity.
Radioresistant tumors showed impaired ferroptosis and regulatory T-cell accumulation, while sorafenib enhanced the response to irradiation in mice.